Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Atrium Medical Center.
Recruitment status was  Recruiting
Information provided by:
Atrium Medical Center Identifier:
First received: September 13, 2005
Last updated: October 29, 2007
Last verified: September 2005
The purpose of this study is to determine which medical treatment is the most effective to terminate a pregnancy.

Condition Intervention Phase
Abortion, Induced
Drug: mifepristone
Drug: misoprostol
Drug: sulprostone
Phase 2

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Atrium Medical Center:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female

Inclusion Criteria:

  • Pregnant women by whom a termination of pregnancy is desired.

Exclusion Criteria:

  • Women with liver/kidney disease
  • Women on long-term use of corticosteroids (> 6 months)
  • Cardiovascular problems
  • Therapy-resistant diabetic women
  • Therapy-resistant asthma/bronchitis
  • Thalassemia
  • Ulcerative colitis
  • Peptic ulcer disease
  • Glaucoma
  • Porphyria
  • Allergic reaction to prostaglandin or mifepristone
  • Women with a prior caesarian section or women with contractions at the start of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00206193

Contact: Suzanne HW Vonken, Dr. 003145-5766666 ext 466825
Contact: F Roumen, Dr. 003145-5766666 ext 466509

Atrium Medisch Centrum Recruiting
Heerlen, Limburg, Netherlands
Contact: Suzanne HW Vonken, Dr.    045-5766666(6825)      
Principal Investigator: Suzanne HW Vonken, Dr.         
Sponsors and Collaborators
Atrium Medical Center
Study Director: F Roumen, Dr. Atrium Medisch Centrum, Heerlen
  More Information Identifier: NCT00206193     History of Changes
Other Study ID Numbers: TOP-protocol 
Study First Received: September 13, 2005
Last Updated: October 29, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Atrium Medical Center:
termination of pregnancy

Additional relevant MeSH terms:
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Abortifacient Agents, Steroidal
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents processed this record on October 26, 2016